Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
BioPharma Dive7d
Novo outlines new late-stage study of obesity drug CagriSema
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...
MedCity News8d
Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects
Last September, Novo Nordisk reported Phase 2 obesity study results showing ... said Wednesday that it is evaluating this drug for further clinical development in this indication.
Ozempic competitors show there’s much to gain in weight loss drugs
Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.
This is Money7d
Novo Nordisk cashes in on obesity and diabetes drugs as profits swell
Novo Nordisk has achieved another blockbuster financial year as the group cheered intense global demand for its obesity and diabetes drugs. The Danish pharmaceutical giant reported turnover from ...
The Financial Times8d
Obesity drug sales surge at Novo Nordisk
Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe’s most valuable listed company almost 5 per cent higher.
Reuters8d
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity ... obesity drug Wegovy, Martin Holst Lange, Novo Nordisk's executive vice president for development, said ...